SGLT2 inhibitors and non-paroxysmal AF Recent studies have shown that sodium dependent glucose cotransporter 2 inhibitors have beneficial effects reducing the risk of incident AF and improving AF prognosis [49–52]. Here, SLC5A2 is linked to atrial fibrillation.